Nasus Pharma Announces Interim Results From Phase 2 Clinical Study Of NS002, Investigational Intranasal Epinephrine Powder Formulation For Treatment Of Anaphylaxis

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen®

91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with NS002 compared to 67% with EpiPen®  

NS002 was well-tolerated with no serious adverse events reported, and a pharmacodynamic response comparable to EpiPen®

Full Phase 2 results expected by the end of first quarter of 2026; Pivotal study initiation planned for fourth quarter of 2026

TEL AVIV, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced positive interim results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The data demonstrated that NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to intramuscular EpiPen® autoinjector.

The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis across two cohorts.  At the interim analysis, the first cohort of 25 participants received NS002 or intramuscular EpiPen® with and without a nasal allergic challenge. The second cohort of 25 participants received repeat doses of NS002 or intramuscular EpiPen® with and without a nasal allergic challenge, evaluating real-world scenarios where multiple administrations may be necessary. The final analysis will include results of all 50 subjects who will have received all treatments.